Symptoms and General Pathology

All Conditions

Nervous System Diseases

Rare Diseases

Cancer Pain

Pain

Neurologic Manifestations

Oculocerebral Syndrome With Hypopigmentation

* Frequency: 100 Hz
* Intensity: individual; TENS should be clearly perceptible but not painful; impulse width is coupled with intensity
* Mode: intensity modulation (40% decrease every 0.5 seconds)
* TENS device: ARTROSTIM® SELECT
* Channels: 2
* Electrodes: 4 (5x5cm), placed on site of pain (a little more proximal if allodynia is present)

Modulated TENS

* Frequency: 100 Hz (conventional for High TENS; Placebo is achieved by reduction of intensity, see below)
* Intensity: The device is on and will be up-regulated together until the first sensation is perceptible. Then the activated device will be down-regulated minimally (no sensation perceptible) and this configuration will be retained.
* Mode: continuous
* TENS device: ARTROSTIM® SELECT
* Channels: 2
* Electrodes: 4 (5x5cm), placed on site of pain (a little proximal if allodynia is present)

Placebo TENS

Gerhild Becker, Prof., MD, MA, MSc

Pain is the most common symptom (ca. 80% of patients) on German Palliative Care units and thus, pain control plays a central role in palliative care.

Transcutaneous electrical nerve stimulation (TENS) is a complementary treatment option for patients who experience suboptimal pain control. However, the evidence for the efficacy of TENS in cancer patients is not unambiguous.

The present study is a double blind, placebo-controlled cross-over trial with a short-term follow-up.

The primary aim of this study is to evaluate the efficacy and safety of TENS for cancer pain reduction in advanced cancer patients.

The secondary aim is the explorative identification of subgroups that benefit or do not benefit from TENS.

Transcutaneous Electrical Nerve Stimulation (TENS) for Advanced Cancer Pain Patients

Transcutaneous Electrical Nerve Stimulation (TENS) for Advanced Cancer Pain Patients - A Randomized, Double-blind, Placebo-controlled Cross-over Pilot Study

11-point Numerical Rating Scale (NRS): 0-10; 0=no pain; 10=pain as bad as you can imagine

11-point NRS 0-100%; 0% = no alleviation, 100% = complete alleviation

7-point verbal rating scale (VRS): 1= "very considerable deterioration", 2= "considerable deterioration", 3= "slight deterioration", 4= "unchanged", 5="slight improvement", 6= "considerable improvement", 7= "very considerable improvement"

Responders: Patients with at least "slight improvement" on VRS (see outcome before) during TENS application

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Transcutaneous Electrical Nerve Stimulation (TENS) for Advanced Cancer Pain Patients	NCT02655289	Advanced Cancer	Modulated TENS Placebo TENS	18 Years -	University Hospital Freiburg
Transcutaneous Electrical Nerve Stimulation (TENS) for Advanced Cancer Pain Patients	NCT02655289	Advanced Cancer	Modulated TENS Placebo TENS	18 Years -	University Hospital Freiburg

Spots Global Cancer Trial Database for modulated tens